Research and development and the "Internet +" into traditional Chinese medicine industry

Development twin-engine [reading] on October 5, 2015, Chinese scientists tu to create new antimalarial drug artemisinin and double hydrogen artemisinin won the Nobel Prize in physiology or medicine, she says the study of revelation is derived from the ancient books of traditional Chinese medicine "elbow backup nasty party". At that time, the traditional Chinese medicine (TCM) once again into public view, online discussion about traditional Chinese medicine industry development also instant heating up.

Traditional Chinese medicine (TCM) as a traditional medicine in our country, because of the complexity of its cure mechanism have not been able to really walk into international medicine market. Recently, the state formally launched "Chinese medicine information construction much starker choices-and graver consequences-in planning" for the establishment of work, determine the build wisdom of traditional Chinese medicine of cloud services platform, implement various kinds of business data sharing and interconnection of traditional Chinese medicine development objectives. This is an important policy of traditional Chinese medicine industry development in our country. Nine power of big data analysis of the existing situation of traditional Chinese medicine industry in our country, research and development levels, and degree of informatization construction. The following conclusions:

More than 1, the traditional Chinese medicine enterprises in our country is not strong;

2, the traditional Chinese medicine enterprises in our country patent consciousness is weak, lack of r&d;

3, the Chinese medicine industry in our country overall low informatization degree, in urgent need of development.

First, Chinese herbal medicine industry development present situation

Chinese herbal medicine industry market size l

In 2014, the Chinese medicine industry in our country growth is slowing, annual gross industrial output value is about 640 billion yuan, accounting for the proportion of medicine industrial output fell by nearly 4%. From the point of traditional Chinese medicine enterprise quantity, year-on-year growth is a new low over the years.

In the past decade has been a steady rise in the number of traditional Chinese medicine enterprises in our country, an average annual compound growth rate of 15.8%, of which 2011 number year-on-year growth of 19.27%, Chinese medicine enterprises reached over the years a maximum growth. Then, because of the global economy downward, traditional Chinese medicine (TCM) industry accumulated problems, such as traditional Chinese medicine standard system is not sound, lack of quality evaluation of technical standard, inadequate research and development, approval of new drugs decline year by year, it is difficult to meet the demand of mass varied health increasingly prominent, such as under the malaise, decline in the number increase year by year, until 2014, the growth rate reduced to 6.12%. Traditional Chinese medicine industry development in our country from the rapid growth into the adjustment period.

L China's TCM industry enterprise survival status quo

In 2014 China's TCM industry personnel scale enterprise by more than ninety percent under 50 people.

Although pharmaceutical industry listed companies such as yunnan baiyao, baiyun mountain, sig income more than in the billions, but the traditional Chinese medicine industry in our country there are still more than ninety percent of the revenues are below do.

Can be seen from the diagram above, traditional Chinese medicine (TCM) industry enterprises generally small scale, low income, micro, small and medium enterprises.

Worth mentioning is that the traditional Chinese medicine industry in our country there are considerable differences in their different niche of market concentration. In 2014, according to data, proprietary Chinese medicine market competition is intense, industry concentration degree is low, the top ten enterprise market share accounted for only 28.7%. Chinese medicine yinpian industry market concentration is higher, the top ten enterprise market share accounted for nearly seventy percent.

From the point of traditional Chinese medicine enterprise scale, large, medium and small businesses, form a pyramid pattern in medium and small enterprises accounted for about three-quarters of the whole traditional Chinese medicine industry. From the point of the technical requirements of the enterprise, Chinese herbal medicine planting and raw material processing technology mature, the enterprise proportion is higher, and the high technical requirements of proprietary Chinese medicine production and plant extract enterprises the proportion is very low. In addition, due to the traditional Chinese medicine production have not been able to establish unified standards, industry science and technology level is not high, the lack of core competitiveness of products, production capacity dispersion, traditional Chinese medicine (TCM) industry presents many, small, scattered phenomenon.

Traditional Chinese medicine enterprises in China regional distribution

Sichuan, guangxi, anhui is Chinese traditional medicine enterprises.

Sichuan province known as "township of the Chinese medicine, Chinese medicine library" of reputation, advantageous geographical climate conditions gave birth to the very rich resources of wild Chinese medicine, is one of the biggest producer of medicinal herbs in China. Varieties of traditional Chinese medicine in China for 12807, sichuan province has 4354 kinds, accounted for 33.99% of the country, the tunnel of 49 kinds of herbs. Among them, 430 kinds of commonly used traditional Chinese medicine in China, in sichuan province has 383 kinds, the first in the nation. Thanks to these natural advantages, Chinese herbal medicine planting most enterprise distribution in sichuan province.

Traditional Chinese medicine (TCM) industry in China listed companies

At present, the traditional Chinese medicine (TCM) companies in the a-share listed companies there are 55, including shenzhen main board listed companies there are 10, main board listed companies in Shanghai have 24, small and medium-sized boards of listed companies has 16, gem listed company has five, main board listed Chinese medicine enterprises are mainly distributed in Shanghai, small and medium-sized board and mainboard. It is worth mentioning that in the past two years the new three board market development by policy support, positive development in micro, small and medium enterprises financing. In the future, the high quality of micro, small and medium enterprises listed on the new three board is also a good choice.

A-shares Chinese medicine enterprise top 10 ranking in 2014

In the past decade has been a steady rise in the number of traditional Chinese medicine enterprises in our country, an average annual compound growth rate of 15.8%, of which 2011 number year-on-year growth of 19.27%, Chinese medicine enterprises reached over the years a maximum growth. Then, because of the global economy downward, traditional Chinese medicine (TCM) industry accumulated problems, such as traditional Chinese medicine standard system is not sound, lack of quality evaluation of technical standard, inadequate research and development, approval of new drugs decline year by year, it is difficult to meet the demand of mass varied health increasingly prominent, such as under the malaise, decline in the number increase year by year, until 2014, the growth rate reduced to 6.12%. Traditional Chinese medicine industry development in our country from the rapid growth into the adjustment period.

L China's TCM industry enterprise survival status quo

In 2014 China's TCM industry personnel scale enterprise by more than ninety percent under 50 people.

Second, the traditional Chinese medicine industry development present situation

Tu won the Nobel Prize greatly enhance the confidence of the people, completely broke the "Chinese scientists and Nobel Prize for" the spell, the scientific community is encouraged. Scientific research without perfect innovation mechanism and a lot of money. However, China's pharmaceutical industry innovation mechanism and r&d spending is still insufficient, especially the Chinese traditional medicine industry.

L to a serious shortage of r&d

New drug research and development need to abundant capital, mature leading technical support and the cycle is long, risk is big. New drugs from paper demonstrates, project establishment, application of basic research, clinical and experiment to declare the production license, the sequence from research to the listed should have at least eight years. In the a-share listed companies in our country, for example, the average enterprise r&d ratio, namely r&d spending accounted for about 4.9% of the revenue. While the average in the field of pharmaceutical chemistry, investment accounted for 4.5%; In the field of medical apparatus and instruments, the ratio of 7%; In the field of biological pharmacy, r&d investment accounted for 8% of the highest; But in the field of traditional Chinese medicine (TCM), enterprise r&d spending accounts for the proportion of revenue is only 2.2%. Whole pharmaceutical r&d investment in China, especially the research and development of traditional Chinese medicine (TCM) is far lower than 14.5% of the American medical industry research and development spending on average, traditional Chinese medicine (TCM) industry in China has a long way to go.

L patent consciousness is weak, difficult for examination and approval of new drugs

's Nobel Prize of antimalarial drug artemisinin has been successfully developed in 1978, but due to the lack of protection of intellectual property rights consciousness, has repeatedly in academic journals, international conference on detailed announced the chemical structure of artemisinin, clinical research and other data, the results were others beat applied for a patent. In traditional Chinese medicine (TCM) in the international market, Chinese patent medicines accounted for only 0.3%, while Japan and South Korea occupy more than 70% of the traditional Chinese medicine patent.

In addition, new drug approval is also one of the reasons in Chinese traditional medicine enterprise development. Currently approved of the country's drug production approval for 169000 pieces of Chinese medicine accounted for only 35.6% of them. In 2013 approved drugs of traditional Chinese medicines accounted for 8.14% of the total approved drugs, and in 2014 approved listing in 507 of new drug approvals, medicine, 466, Chinese medicine is only 24, accounted for only 4.73%. Passing rate of examination and approval of new drug of TCM, therefore, more and more low, so many enterprises to research and development has high rate of approved drugs.

Three, "Internet + Chinese traditional medicine" status

In the whole industry chain from the traditional Chinese medicine industry, the Internet application in circulation at the leading level. Because in the circulation of goods, the Internet has to eliminate information asymmetry and lower transaction costs.

In terms of traditional Chinese medicine circulation, on August 22, the first Chinese electricity standard - "standard of Chinese herbal medicine products electronic trading specification", it provides policy guarantee for the development of the Internet + traditional Chinese medicine.

Chinese herbal medicine production areas scattered, medicinal plant is self-employed, the unequal phenomenon is serious, information often appears imbalance, production and sales prices plummeted, the intermediate links layers of premium and other issues. These problems can cause "herbalist was forced to sell Chinese herbal medicine, Chinese medicine production enterprises, to purchase Chinese herbal medicine" phenomenon, the interests of both parties suffer, severely restricted the healthy development of Chinese traditional medicine industry.

As early as 2010, sig pharmaceutical compiled the sig (puning) Chinese medicinal herbs price index, as south China medicine market "barometer" of prices. Then, and by means of the "Internet +" dongfeng, built the e medicine valley medicines bulk trading platform. Medicinal materials merchants and drug firms through e medicine valley platform to achieve the "orders online and offline physical delivery" shortcut way to trade, it is the combination of traditional Chinese medicine (TCM) industry and the Internet a success story.

In terms of drug sales, the development of medical electrical contractor is in full swing. As of August this year, our country for Internet medicine trading services qualification certificate of C 329 enterprises, of which about 200 companies using Tmall platform for drug sales. According to statistics, in the first half, Tmall platform over-the-counter drug sales of 622 million yuan, and in the national over-the-counter directory, varieties of traditional Chinese medicine non-prescription drugs alone accounted for 80%. Moreover, as a traditional medicine, the consumer bought for reasons of drug safety factors make medicine more inclined to traditional Chinese medicine (TCM), and we believe that Chinese medicine on Internet platform achieved good sales performance.

At present, our country medicine electricity permeability is low, less than 1%, compared with 30% of America's permeability, also there is a huge gap, it also suggests that our country medicine electricity broad development space. In the future, along with the further opening up policy, medical electrical dealer market scale or explosive growth.

In terms of traditional Chinese medicine production, due to the complexity of traditional Chinese medicine pharmaceutical ingredients, active ingredients to cure the analysis and the quantitative is very difficult, and is strongly influenced by traditional Chinese medicine raw materials, the traditional Chinese medicine (TCM) automation, digital production caused great difficulties. At present, the Internet application in Chinese traditional medicine enterprise production is not common.

To sum up, the Chinese medicine industry in our country informationization degree is still in a lower level, in urgent need of rapid development. Nowadays, smooth closing of the fifth plenary session of the 18, "much starker choices-and graver consequences-in planning" will be formally established, will promote the traditional Chinese medicine industry in our country gradually achieve modernization and informatization development.